Proteomics and Metabolomics of Body Fluid in Patients With Narcolepsy
Qilu Hospital of Shandong University
60 participants
Sep 1, 2022
OBSERVATIONAL
Conditions
Summary
Narcolepsy (NRL) is a rare chronic central nervous system dysfunction disease, which is more common in children and adolescents, and less common in adults. Its typical clinical features include excessive daytime sleep, paroxysmal cataplexy, sleep paralysis and sleep hallucination. In addition to the above typical manifestations, patients with narcolepsy can also manifest as hyperappetite, weight gain, multiple dreams, sleep fragmentation, anxiety and depression and other emotional disorders. In particular, in narcolepsy type 1 with cataplexy, cataplexy episodes can be confused with falls caused by seizures, transient ischemic attacks or neuromuscular disorders, or even mental conversion disorders. Due to its diverse clinical symptoms, it is easy to be missed and misdiagnosed. At present, the pathogenesis of narcolepsy is still unclear, and its pathogenesis may be related to immune, genetic, environmental, infection, central nervous system degeneration and other factors. This study aims to investigate the changes of body fluid proteomics and metabolomics in patients with narcolepsy, and to provide an important basis for the pathogenesis of narcolepsy.
Eligibility
Inclusion Criteria1
- All patients met the diagnostic criteria of the International Classification of Sleep Disorders, Third edition (ICSD-3).
Exclusion Criteria6
- primary hypersomnia or hypersomnia due to shift work, sleep deprivation and other sleep rhythm disturbances;
- excessive sleep due to drug abuse;
- suffering from Parkinson's disease, Alzheimer's disease and other nervous system diseases and mental diseases;
- complicated with heart, lung, liver, kidney, blood endocrine system and other basic diseases, or acute chronic infection in a short period of time;
- Use of sedatives, hypnotics, antidepressants, lithium and dopamine receptor antagonists for two weeks before examination;
- patients who cannot cooperate with PSG and MSLT due to various factors.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06279247